Muscarinic receptor antagonists for overactive bladder

BJU International

Volumn 100, Issue 5, 2007, Pages 987-1006

  Abrams, Paul ^a   Andersson, Karl Erik ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antimuscarinic; Darifenacin; Muscarinic receptor antagonist; Overactive bladder; Oxybutynin; Solifenacin; Tolterodine; Trospium

Indexed keywords

ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CAPSAICIN; DARIFENACIN; DICYCLOVERINE; DOXAZOSIN; EMEPRONIUM; FLAVOXATE; IMIPRAMINE; INDOMETACIN; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; OPIATE; OXYBUTYNIN; OXYPHENCYCLIMINE; PHOSPHODIESTERASE INHIBITOR; PROPANTHELINE BROMIDE; PROPIVERINE; PURINERGIC RECEPTOR BLOCKING AGENT; RESINIFERATOXIN; RHO KINASE INHIBITOR; SOLIFENACIN; TAMSULOSIN; TERODILINE; TOLTERODINE; TROSPIUM CHLORIDE;

ABDOMINAL CRAMP; BLADDER NECK STENOSIS; BLADDER WALL; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC NERVE; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DETRUSOR DYSSYNERGIA; DIZZINESS; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; MICTURITION REFLEX; MONOTHERAPY; MUSCLE DENERVATION; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RECEPTOR BINDING; RECEPTOR SENSITIVITY; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SMOOTH MUSCLE FIBER; SOMNOLENCE; SYNAPTOSOME; TACHYCARDIA; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; UROTHELIUM; XEROSTOMIA;

ANIMALS; GUINEA PIGS; HUMANS; MALE; MICE; MUSCARINIC ANTAGONISTS; RATS; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 35148841097     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07205.x     Document Type: Review

References (212)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6
3. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36
4. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 15
5. Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004 7 : 455 63
6. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int 2003 92 : 948 54
7. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001 57 : 1044 50
8. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002 60 (Suppl. 1 82 9
9. Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999 64 : 419 28
10. Andersson KE, Wein AJ. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev 2004 56 : 581 631
11. Morrison J, Birder L, Craggs M et al. Incontinence. In Abrams P, Cardozo L, Khoury S, Wein A, eds 3rd International Consultation on Incontinence. France : Health Publication Ltd, 2005 : 811 54
12. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006 147 (Suppl. 2 S25 40
13. Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002 60 : 13 21
14. Griffiths D, Holstege G, Dalm X, de Wall H. Control and coordination of bladder and urethral function in the brainstem of the cat. Neurourol Urodyn 1990 9 : 63 82
15. Blok BF, Holstege G. Two pontine micturition centers in the cat are not interconnected directly: implications for the central organization of micturition. J Comp Neurol 1999 403 : 209 18
16. Blok BF. Central pathways controlling micturition and urinary continence. Urology 2002 59 (Suppl. 1 13 7
17. Ishiura Y, Yoshiyama M, Yokoyama O, Namiki M, de Groat WC. Central muscarinic mechanisms regulating voiding in rats. J Pharmacol Exp Ther 2001 297 : 933 9
18. Ishizuka O, Gu BJ, Yang ZX, Nishizawa O, Andersson KE. Functional role of central muscarinic receptors for micturition in normal conscious rats. J Urol 2002 168 : 2258 62
19. Kono M, Nakamura Y, Ishiura Y, Komatsu K, Kontani H, Namiki M. Central muscarinic receptor subtypes regulating voiding in rats. J Urol 2006 175 : 353 7
20. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001 166 : 550 3
21. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003 22 : 105 8
22. Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 2004 64 : 1643 56
23. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002 4 (Suppl. 4 S7 18
24. Drake M, Gillespie J, Hedlund P, Harvey I, Lagou M, Andersson KE. Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Auton Autacoid Pharmacol 2006 26 : 261 6
25. De Groat WC, Booth AM, Yoshimura N. Neurophysiology of micturition and its modification in animal models of human disease. In Maggi CA ed. Nervous Control of the Urogenital System. London : Harwood Academic Publisher, 1993 : 227 90
26. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004 63 (Suppl. 1 17 23
27. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur Urol 2003 43 : 1 5
28. Coolsaet BL, Van Duyl WA, Van Os-Bossagh P, De Bakker HV. New concepts in relation to urge and detrusor activity. Neurourol Urodyn 1993 12 : 463 71
29. Coolsaet BL. Bladder compliance and detrusor activity during the collection phase. Neurourol Urodyn 1985 4 : 263 73
30. Drake MJ, Harvey IJ, Gillespie JI. Autonomous activity in the isolated guinea pig bladder. Exp Physiol 2003 88 : 19 30
31. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int 2004 93 : 478 83
32. Drake MJ, Harvey IJ, Gillespie JI, Van Duyl WA. Localized contractions in the normal human bladder and in urinary urgency. BJU Int 2005 95 : 1002 5
33. Lagou M, Gillespie J, Kirkwood T, Harvey I, Drake MJ. Muscarinic stimulation of the mouse isolated whole bladder: physiological responses in young and ageing mice. Auton Autacoid Pharmacol 2006 26 : 253 60
34. Brading AF. Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function. J Physiol 2006 570 : 13 22
35. Brading AF. A myogenic basis for the overactive bladder. Urology 1997 50 (Suppl. 57 73
36. Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J Urol 1993 150 : 1668 80
37. Harrison SC, Hunnam GR, Farman P, Ferguson DR, Doyle PT. Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 1987 60 : 519 22
38. Mostwin JL. Pathophysiology: the varieties of bladder overactivity. Urology 2002 60 (Suppl. 1 22 7
39. Fowler CJ, Beck RO, Gerrard S, Betts CD, Fowler CG. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994 57 : 169 73
40. Wiseman OJ, Brady CM, Hussain IF et al. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J Urol 2002 168 : 2040 5
41. Fowler CJ. Bladder afferents and their role in the overactive bladder. Urology 2002 59 (Suppl. 1 37 42
42. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998 50 : 279 90
43. Sigala S, Mirabella G, Peroni A et al. Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 2002 60 : 719 25
44. Hinata N, Shirakawa T, Okada H, Achaya B, Kamidono S, Gotoh A. Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder. Mol Diagn 2004 8 : 17 22
45. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subytpes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995 273 : 956 66
46. Yamaguchi O, Shishido K, Tamura K, Ogawa T, Fujimura T, Ohtsuka M. Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J Urol 1996 156 : 1208 13
47. 3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 2006 176 : 367 73
48. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 1996 48 : 531 65
49. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial, and projectional. Auton Autocoid Pharmacol 2002 22 : 133 45
50. Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol 2006 26 : 219 33
51. 3 subtype. Proc Natl Acad Sci USA 2000 97 : 9579 84
52. 3 receptors. J Urol 2004 172 : 2460 4
53. 3 muscarinic receptors in the rat urinary bladder following partial outlet obstruction. J Urol 1999 161 : 1644 50
54. Andersson KE, Holmquist F, Fovaeus M, Hedlund H, Sundler R. Muscarinic receptor stimulation of phosphoinositide hydrolysis in the human isolated urinary bladder. J Urol 1991 146 : 1156 9
55. 3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 1995 154 : 1241 5
56. Jezior JR, Brady JD, Rosenstein DI, McCammon KA, Miner AS, Ratz PH. Dependency of detrusor contractions on calcium sensitization and calcium entry through LOE-908-sensitive channels. Br J Pharmacol 2001 134 : 78 87
57. Wibberley A, Chen Z, Hu E, Hieble JP, Westfall TD. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle. Br J Pharmacol 2003 138 : 757 66
58. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004 309 : 1148 53
59. 3 muscarinic receptor activation of urinary bladder contractile signal transduction. II. Denervated rat bladder. J Pharmacol Exp Ther 2006 316 : 875 80
60. 2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004 172 : 748 52
61. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997 120 : 1409 18
62. 2 signaling in smooth muscle cells. Life Sci 1999 64 : 437 42
63. Bonev AD, Nelson MT. Muscarinic inhibition of ATP-sensitive K+ channels by protein kinase C in urinary bladder smooth muscle. Am J Physiol 1993 265 : C1723 8
64. 2+-activated K+ channels in rat bladder smooth muscle. Int J Urol 2002 9 : 689 96
65. 2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 2005 313 : 368 78
66. 2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol 1998 275 : R1654 60
67. 2 receptors in genito-urinary smooth muscle pathology. Life Sci 1999 64 : 429 36
68. Braverman AS, Tallarida RJ, Ruggieri MR. Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol 2002 283 : R663 8
69. 3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder. J Pharmacol Exp Ther 2006 316 : 869 74
70. Kumar V, Cross RL, Chess-Williams R, Chapple CR. Recent advances in basic science for overactive bladder. Curr Opin Urol 2005 15 : 222 6
71. 2. Am J Physiol Regul Integr Comp Physiol 2003 285 : R701 8
72. Stevens L, Chess-Williams R, Chapple C. Muscarinic receptor function in the idiopathic overactive bladder. J Urol 2004 171 (Suppl. 140 1, P527
73. Stevens L, Chapple C, Tophill P, Chess-Williams R. A comparison of muscarinic receptor-mediated function in the normal and the neurogenic overactive bladder. J Urol 2004 171 (Suppl. 143, P535
74. 2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004 286 : R874 80
75. 3H] acetylcholine in the rabbit urinary bladder. Eur J Pharmacol 1995 281 : 1 8
76. Inadome A, Yoshida K, Takahashi W et al. Prejunctional muscarinic receptors modulating acetylcholine release in rabbit detrusor smooth muscles. Urol Int 1998 61 : 135 41
77. Somogyi GT, de Groat WC. Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Syst 1992 37 : 89 98
78. 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther 1995 274 : 458 68
79. 3H-acetylcholine release in the rat isolated urinary bladder. J Pharmacol Exp Ther 1997 283 : 750 6
80. 4 receptor subtype. Br J Pharmacol 2000 129 : 493 500
81. Somogyi GT, de Groat WC. Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci 1999 64 : 411 8
82. Somogyi GT, Zernova GV, Yoshiyama M, Rocha JN, Smith CP, de Groat WC. Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem Int 2003 43 : 73 7
83. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005 144 : 1089 99
84. Fovaeus M, Fujiwara M, Hogestatt ED, Persson K, Andersson KE. A non-nitrergic smooth muscle relaxant factor released from rat urinary bladder by muscarinic receptor stimulation. J Urol 1999 161 : 649 53
85. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000 129 : 416 9
86. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003 62 (Suppl. 5B 3 10
87. Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J Urol 2005 174 : 2032 6
88. Hedlund P, Streng T, Lee T, Andersson KE. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin-treated conscious rats. J Urol 2007 178 : 326 31
89. De Laet K, De Wachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006 25 : 156 61
90. 3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007 [Epub ahead of print]
91. Boy S, Schurch B, Nehring G, Knapp P, Karsentry G, Reitz A. The effect of tolterodine on sensations evoked by electrical stimulation and bladder filling sensations. Eur Urol Suppl 2006 5 : 223, abstract 804
92. Andersson KE. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 2004 3 : 46 53
93. Wall LL. The management of detrusor instability. Clin Obstet Gynecol 1990 33 : 367 77
94. Wein AJ. Pharmacologic options for the overactive bladder. Urology 1998 51 (Suppl. 43 7
95. Wiklund I. Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life. Fundam Clin Pharmacol 2004 18 : 351 63
96. Fairclough DL. Patient reported outcomes as endpoints in medical research. Stat Methods Med Res 2004 13 : 115 38
97. Gordon D, Groutz A. Evaluation of female lower urinary tract symptoms: overview and update. Curr Opin Obstet Gynecol 2001 13 : 521 7
98. Nygaard I. Physiologic outcome measures for urinary incontinence. Gastroenterology 2004 126 (Suppl. S99 105
99. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Qual Life Res 2002 11 : 563 74
100. Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zycyzynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ). Neurourol Urodyn 2005 24 : 215 25
101. Reese PR, Pleil AM, Okano GJ, Kelleher CJ. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003 12 : 427 42
102. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003 326 : 841 4
103. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005 48 : 5 26
104. Dorschner W, Stolzenburg JU, Griebenow R et al. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine]. Aktuelle Urol 2003 34 : 102 8
105. Jünemann KP, Hessdoerfer E, Unamba-Oparah I et al. Propiverine hydrochloride immediate (IR) and extended release (ER): comparison of efficacy and tolerability in patients with overactive bladder. International Continence Society 34th Annual Meeting; 2004; Paris, France. 2004, Abstract 143
106. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on quality of life in overactive bladder: a systematic review and meta-analysis. Urology 2006 68 (Suppl. 2A 38 48
107. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005 95 : 993 1001
108. Sussman DO, Kraus SR, Carlsson M, Guan Z. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007 23 : 777 81
109. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004 45 : 420 9
110. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006 97 : 540 6
111. Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol 2004 171 : 752 6
112. Sanctura® (Trospium chloride). Full Prescribing Information. Odyssey Pharmaceuticals Inc., Indevus. Pharmaceuticals Inc., Lexington, MA, and East Hanover, NJ, USA 2004
113. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003 4 : 436 40
114. Ditropan® XL (oxybutynin chloride). Full Prescribing Information. Ortho-McNeil Pharmaceutical Inc., Raritan, NJ, USA 2004
115. Detrol® (tolterodine tartrate). Full Prescribing Information. Pharmacia & Upjohn Company, Kalamazoo, MI, USA 2003
116. VESIcare® (Solifenacin succinate). Full Prescribing Information. Yamanouchi Pharma America Inc. and GlaxoSmithKline, Norman, OK, USA 2004
117. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 2003 20 : 857 64
118. Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Invest Drugs 2004 5 : 40 9
119. Wuest M, Weiss A, Waelbroeck M et al. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 2006 374 : 87 97
120. 3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004 310 : 1255 65
121. Ohtake A, Ukai M, Hatanaka T et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 492 : 243 50
122. Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997 327 : 195 207
123. Ikeda K, Kobayashi S, Suzuki M et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002 366 : 97 103
124. Maruyama S, Oki T, Otsuka A et al. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder. J Urol 2006 175 : 365 9
125. Nagao M, Kaneko S, Hirota T, Isogai M, Shimizu H. [Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs]. Nippon Yakurigaku Zasshi 1999 113 : 157 66
126. Burgio KL, Locher JL, Goode PS et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998 280 : 1995 2000
127. Dmochowski RR, Davila GW, Zinner NR et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 168 : 580 6
128. Oxytrol (Oxybutynin Transdermal System). Full Prescribing Information. Watson Pharmaceuticals Inc., Corona, CA, USA 2005
129. Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol 1997 15 : 144 51
130. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001 49 : 700 5
131. Detrol (Tolterodine tartrate tablets). Full Prescribing Information. Pharmacia & Upjohn Company, Kalamazoo, MI, USA 2003
132. Abrams P, Kaplan SA, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006 175 : 999 1004
133. Detrol LA (Tolterodine tartrate extended release capsules). Full Prescribing Information. Pharmacia & Upjohn Company, Kalamazoo, MI, USA 2003
134. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z 037 Study Group. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006 67 : 731 6
135. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002 50 : 799 807
136. Alloussi S, Luval KU, Eckert R et al. Trospium chloride in patients with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res 1998 1 : 439 51
137. Cardozo L, Chapple CR, Toozs-Hobson P et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000 85 : 659 64
138. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004 171 : 2311 5
139. Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004 172 : 1919 24
140. Enablex® (Darifenacin). Full Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 2004
141. 3-selective receptor antagonist. BJU Int 2005 95 : 580 6
142. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998 81 : 801 10
143. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999 161 : 1809 12
144. Barkin J, Corcos J, Radomski S et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004 26 : 1026 36
145. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000 85 : 793 8
146. Davila GW, Daugherty CA, Sanders SW Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 : 140 5
147. Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999 10 : 283 9
148. Halaska M, Ralph G, Wiedemann A et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003 20 : 392 9
149. Homma Y, Paick JS, Lee JG, Kawabe K Japanese and Korean Tolterodine Study Group. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003 92 : 741 7
150. Lee JG, Hong JY, Choo MS et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. Int J Urol 2002 9 : 247 52
151. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001 165 : 1452 6
152. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000 95 : 718 21
153. Diokno AC, Appell RA, Sand PK et al; OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003 78 : 687 95
154. Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct 2004 15 : 243 8
155. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 : 237 42
156. Junemann KP, Halaska M, Rittstein T et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005 48 : 478 82
157. Stohrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ Propiverine Investigator Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity - results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007 51 : 235 42
158. Junemann KP, Hessdorfer E, Unamba-Oparah I et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int 2006 77 : 334 9
159. Chapple CR, Arano P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004 93 : 71 7
160. Swift S, Garely A, Dimpfl T, Payne C Tolterodine Study Group. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2003 14 : 50 5
161. van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001 57 : 414 21
162. Chapple CR, Martinez-Garcia R, Selvaggi L et al; STAR Study Group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 48 : 464 70
163. Wallis RM, Napier CM. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 1999 64 : 395 401
164. Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf 2004 27 : 1043 57
165. Ishizaka N, Noda M, Yokoyama S, Kawasaki K, Yamamoto M, Higashida H. Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 1998 787 : 344 7
166. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006 440 : 463 9
167. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004 350 : 1013 22
168. Rigel DF, Lipson D, Katona PG. Excess tachycardia: heart rate after antimuscarinic agents in conscious dogs. Am J Physiol 1984 246 : H168 73
169. Chassaing C, Boucher M, Breysse C, Duchene-Marullaz P. Contribution of vagal blockade to the tachycardia induced by the antimuscarinic agents atropine and pirenzepine. J Auton Pharmacol 1992 12 : 359 68
170. Hussain RM, Hartigan-Go K, Thomas SH, Ford GA. Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996 41 : 73 5
171. Layton D, Pearce GL, Shakir SA. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf 2001 24 : 703 13
172. Detrol LA® (tolterodine tartrate). Full Prescribing Information.
173. Dorschner W, Stolzenburg JU, Griebenow R et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000 37 : 702 8
174. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005 174 : 2273 6
175. Lee JY, Kim HW, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004 94 : 817 20
176. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003 169 : 2253 6
177. Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005 174 : 1334 8
178. Saitoh H, Yamada T, Oshima H et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and/or urinary incontinence. Jpn J Urol Surg 1999 12 : 525 36
179. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006 296 : 2319 28
180. Kay GG, Granville LJ. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly. Clin Ther 2005 27 : 127 38
181. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991 11 : 3218 26
182. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998 46 : 8 13
183. Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 2005 27 : 144 53
184. Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004 5 : 423 6
185. 3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. 19th Congress of the European Association of Urology; 2004 March 24-27; Vienna, Austria 2004
186. Diefenbach K, Arold G, Wollny A, Schwantes U, Haselmann J, Roots I. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int 2005 95 : 346 9
187. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol 2003 60 : 771 3
188. Williams SG, Staudenmeier J. Hallucinations with tolterodine. Psychiatr Serv 2004 55 : 1318 9
189. Tsao JW, Heilman KM. Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003 349 : 2274 5
190. Ditropan® (oxybutynin chloride). Full Prescribing Information. ALZA Corporation, Mountain View, CA, USA 1998
191. Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 2002 59 : 428 32
192. Sommer BR, O'Hara R, Askari N, Kraemer HC, Kennedy WA. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. J Urol 2005 173 : 2125 7
193. Grigoleit U, Murtz G, Laschke S et al. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity - a retrospective study. Eur Urol 2006 49 : 1114 21
194. Lopez Pereira P, Miguelez C, Caffarati J, Estornell F, Anguera A. Trospium chloride for the treatment of detrusor instability in children. J Urol 2003 170 : 1978 81
195. Bolduc S, Upadhyay J, Payton J et al. The use of tolterodine in children after oxybutynin failure. BJU Int 2003 91 : 398 401
196. Ayan S, Kaya K, Topsakal K, Kilicarslan H, Gokce G, Gultekin Y. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. BJU Int 2005 96 : 411 4
197. Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol 2006 13 : 105 8
198. Nijman RJ, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. J Urol 2005 173 : 1334 9
199. Nijman RJ, Borgstein NG, Ellsworth P, Siggaard C. Long-term tolerability of tolterodine extended release in children 5-11 years of age: Results from a 12-Month, Open-Label Study. Eur Urol 2007 : [Epub ahead of print]
200. Reinberg Y, Crocker J, Wolpert J, Vandersteen D. Therapeutic efficacy of extended release oxybutynin chloride, and immediate release and long acting tolterodine tartrate in children with diurnal urinary incontinence. J Urol 2003 169 : 317 9
201. Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoorne J, Vande Walle J. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder. Eur Urol 2004 45 : 240 4
202. Umlauf MG, Goode S, Burgio KL. Psychosocial issues in geriatric urology: problems in treatment and treatment seeking. Urol Clin North Am 1996 23 : 127 36
203. Marschall-Kehrel D, Roberts RG, Brubaker L. Patient-reported outcomes in overactive bladder: the influence of perception of condition and expectation for treatment benefit. Urology 2006 68 (Suppl. 2A 29 37
204. Skoner MM, Haylor MJ. Managing incontinence: women's normalizing strategies. Health Care Women Int 1993 14 : 549 60
205. Milne J. The impact of information on health behaviors of older adults with urinary incontinence. Clin Nurs Res 2000 9 : 161 76
206. Abrams P, Andersson KE, Brubaker L et al. 3rd International Consultation on Incontinence, Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence: International Continence Society 2005. Available at: http://www.icsoffice.org/documents/ici_pdfs_3/v2.pdf/summary.pdf. Accessed June 2007
207. Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005 22 : 381 94
208. Malone-Lee J, Henshaw DJ, Cummings K. Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response. BJU Int 2003 92 : 415 7
209. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 350 : 786 99
210. Sitzia J, Wood N. Patient satisfaction: a review of issues and concepts. Soc Sci Med 1997 45 : 1829 43
211. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001 41 : 691 721
212. Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002 168 : 1897 913